Genitourinary cancers
4 trials- 2024EV-302 / KEYNOTE-A39Urothelial 1LIn 886 patients with untreated advanced urothelial carcinoma, enfortumab vedotin + pembrolizumab improved progression-free and overall survival compared with platinum-based chemotherapy.
- 2021VISIONmCRPC PSMA-RLTIn 831 patients with PSMA-positive mCRPC after androgen-receptor signalling inhibition and taxane chemotherapy, 177Lu-PSMA-617 + standard care improved radiographic PFS and overall survival compared with standard care alone.
- 2018CheckMate-214Advanced RCCIn 1,096 patients with untreated advanced clear-cell renal cell carcinoma, nivolumab + ipilimumab improved overall survival in intermediate/poor-risk patients compared with sunitinib.
- 2015CHAARTEDmHSPCIn 790 patients with metastatic hormone-sensitive prostate cancer, ADT + docetaxel improved overall survival compared with ADT alone.